Fabry Disease Treatment Market by Product Type, by Application, by Geography – Forecast to 2028


Report - ID613087 | 12 July, 2019 | Healthcare | 100 pages | Report Type (Global) | Publisher Name - RFM

Market Analysis Insights 
The fabry disease treatment market is expected to grow globally with an estimated CAGR of 10.1% to reach USD 4.5 billion by 2028. Expanding base of patients suffering with fabry disease coupled with increased adoption of novel therapies such as chaperone treatment, extensive R&D activities and potential approval of promising pipeline products including substrate reduction therapies and enzyme replacement therapies are some of the main market drivers of this market. 

Market Segment
The Market is segmented based on Treatment
• Enzyme Replacement Therapy (ERT)
• Chaperone Treatment
• Substrate Reduction Therapy (SRT)
• Gene Therapy
• Pharmaceutical Formulations Containing Agalsidase Alpha
• Analgesics
• Anticonvulsants
• NSAIDS

The Market is segmented based on Distribution Channel
• Hospitals
• Clinics
The above segmentation is covered for all countries and regions listed below
• North and South America
o U.S.
o Canada
o Mexico
o Brazil
o Rest of Americas
• Europe
o Germany
o France
o U.K.
o Italy 
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Australia
o Rest of APAC
• Middle East and Africa
Vendor Landscape Competitive Research
The major players in fabry disease treatment market are Sanofi, Shire, Amicus Therapeutics, Inc., ISU ABXIS, JCR Pharmaceuticals Co Ltd., Plant-Based Proteins, Idorsia Pharmaceuticals Ltd, AVROBIO, Inc., Greenovation Biotech GmbH, Moderna, Inc., Green Cross Pharma Pte Ltd
Leave a Message